Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure

• Published in: European journal of heart failure 2012-05, Vol.14 (5), p.540-548
• Main Authors: Núñez, Julio, González, Miguel, Miñana, Gema, Garcia-Ramón, Rafael, Sanchis, Juan, Bodí, Vicent, Núñez, Eduardo, Puchades, Maria Jesús, Palau, Patricia, Merlos, Pilar, Llàcer, Angel, Miguel, Alfonso
• Format: Article
• Language: English
• Subjects: advanced congestive heart failure; Ambulatory Care - methods; Biomarkers - blood; continuous ambulatory peritoneal dialysis; Female; fluid overload; Glomerular Filtration Rate; Heart Failure - complications; Heart Failure - physiopathology; Heart Failure - therapy; Humans; Kidney - physiopathology; Male; Peritoneal Dialysis, Continuous Ambulatory - methods; Prospective Studies; renal failure; Renal Insufficiency - complications; Renal Insufficiency - therapy; Severity of Illness Index; Surveys and Questionnaires
• ISSN: 1388-9842; 1879-0844
• DOI: 10.1093/eurjhf/hfs013

Aims Continuous ambulatory peritoneal dialysis (CAPD) has been proposed as an additional therapeutic resource for patients with advanced congestive heart failure (CHF). The objective of this study was to determine the therapeutic role of CAPD, in terms of surrogate endpoints, in the management of patients with advanced CHF and renal dysfunction. Methods and results A total of 57 candidates with New York Heart Association (NYHA) class III/IV CHF, renal dysfunction (glomerular filtration rate < 60 mL/min/1.73 m2), persistent fluid congestion despite loop diuretic treatment, and at least two previous hospitalizations for acute heart failure (AHF) were invited to be included in the CAPD programme; however, 25 patients were finally included. The primary outcome was evaluated by the change at 6 and 24 weeks for the Minnesota Living With Heart Failure Questionnaire (MLWHFQ), the 6 min walk test (6MWT), NYHA class, serum natriuretic peptides [brain natriuretic peptide (BNP) and N‐terminal proBNP (NT‐proBNP)], serum carbohydrate antigen 125 (CA125), and hospitalization rates for AHF. CAPD was associated with a substantial improvement in the MLWHFQ (−21.3, P < 0.001; and −20.4, P < 0.001), the 6MWT (54.0, P < 0.001; and 45.6, P = 0.023), and NYHA class (−1.0, P < 0.001; and −1.4, P < 0.001) at 6 and 24 weeks, respectively. The Ln(CA125) decreased markedly (−0.8, P = 0.003; and −0.98, P = 0.003), with no effect on BNP and NT‐proBNP. There was a marked reduction in the number of days hospitalized for AHF (6 month post‐CAPD vs. 6 months pre‐CAPD: −84%; P < 0.001). Conclusions In advanced CHF and renal dysfunction, CAPD was associated with short/mid‐term improvement in severity parameters, with an acceptable rate of side effects.